Personalis, Inc. (NASDAQ:PSNL) CEO John Stephen West sold 110,000 shares of Personalis stock in a transaction that occurred on Tuesday, June 8th. The shares were sold at an average price of $22.43, for a total transaction of $2,467,300.00. Following the sale, the chief executive officer now directly owns 670,520 shares of the company’s stock, valued at approximately $15,039,763.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of PSNL stock opened at $23.30 on Friday. The business’s fifty day simple moving average is $22.28. The firm has a market capitalization of $1.02 billion, a P/E ratio of -19.58 and a beta of 1.49. Personalis, Inc. has a 12-month low of $11.05 and a 12-month high of $53.46.
Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Wednesday, May 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. Personalis had a negative return on equity of 21.21% and a negative net margin of 55.43%. On average, equities research analysts forecast that Personalis, Inc. will post -1.62 earnings per share for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the company. NEXT Financial Group Inc purchased a new stake in shares of Personalis during the fourth quarter valued at $25,000. AdvisorNet Financial Inc purchased a new stake in shares of Personalis during the fourth quarter valued at $27,000. Penserra Capital Management LLC grew its holdings in shares of Personalis by 171.2% during the fourth quarter. Penserra Capital Management LLC now owns 895 shares of the company’s stock valued at $32,000 after buying an additional 565 shares during the last quarter. Banque Cantonale Vaudoise purchased a new stake in shares of Personalis during the fourth quarter valued at $33,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Personalis during the fourth quarter valued at $47,000. 67.53% of the stock is currently owned by hedge funds and other institutional investors.
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.
Featured Story: Cost of Capital Explained
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.